SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Casey's General Stores issued a press release on September 8, 2026, announcing financial results for the first quarter ended July 31, 2026, including diluted EPS of $7.37, net income of $273.7 million, EBITDA of $485.1 million, same-store sales data, and fiscal 2027 guidance.
View raw filing on EDGAR →United Natural Foods issued a press release on September 8, 2026, reporting financial results for the fourth quarter and full fiscal year ended August 1, 2026, including net sales, net income, EPS, Adjusted EBITDA, free cash flow, segment performance, and fiscal 2027 guidance.
View raw filing on EDGAR →This exhibit is a press release announcing Canaan Inc.'s unaudited financial results for the second quarter 2026, including total revenues of US$31.9 million, net loss of US$97.6 million, and key operational metrics (243 BTC mined, record 1,915 BTC treasury). The disclosure includes detailed financial statements, management commentary, and forward guidance for Q3 2026, all hallmarks of a quarterly earnings release. Material to investors as it discloses significant operating losses, substantial non-cash impairments (US$25.3 million inventory write-down, US$9.2 million property impairment), and cryptocurrency fair-value losses.
View raw filing on EDGAR →This exhibit is a press release announcing Waterdrop Inc.'s unaudited financial results for Q2 2026 (three and six months ended June 30, 2026), including net operating revenue of RMB1,448.2 million (up 72.8% YoY), operating profit of RMB111.3 million, and net profit of RMB125.8 million. The disclosure also announces a cash dividend of US$0.03 per ADS and a new share repurchase program. This is a classic earnings release event disclosing quarterly financial results.
View raw filing on EDGAR →This exhibit is a press release announcing Kenon Holdings' Q2 2026 financial results, including consolidated revenue of $379 million, profit of $15 million, and Adjusted EBITDA of $131 million for the period ended June 30, 2026. The document explicitly states "Kenon Holdings Reports Q2 2026 Results and Additional Updates" and provides detailed financial performance metrics, revenue breakdowns by geography, and cost analysis—all hallmarks of a quarterly earnings release. Material updates on the Hadera Expansion Project, Series E bond issuance, and Peru arbitration award receipt are disclosed alongside the results.
View raw filing on EDGAR →This is a press release announcing positive topline results from the CHAPTER-3 pivotal Phase 3 clinical trial of deucrictibant XR for HAE prophylaxis. The disclosure reports that the primary endpoint was met with 83% attack rate reduction versus placebo (p<0.0001), all secondary efficacy endpoints were met with statistical significance, and the drug demonstrated a well-tolerated safety profile. While technically a clinical trial result rather than financial earnings, this constitutes a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and regulatory prospects, warranting classification as an earnings_release analog for a clinical-stage biotech company.
View raw filing on EDGAR →ABM Industries issued a press release on September 8, 2026, announcing financial results for the fiscal third quarter ended July 31, 2026, including quarterly revenue of $2.3 billion (up 4.2%), net income of $49.7 million (up 19%), adjusted EPS of $1.04 (up 19%), and adjusted EBITDA of $139.6 million (up 11%), along with raised full-year guidance.
View raw filing on EDGAR →The filing discloses enGene's financial results for the three and nine months ended July 31, 2026, including operating expenses ($34.0 million for Q3 2026), net loss ($32.5 million or $0.47 per share), and cash position ($266.3 million). The press release attached as Exhibit 99.1 is a standard earnings announcement with financial metrics and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings releases.
View raw filing on EDGAR →This exhibit is a clinical trial data presentation for CHAPTER-3 Phase 3 study of deucrictibant XR for long-term prophylaxis of hereditary angioedema (HAE). While it discloses positive topline results (83% attack rate reduction vs. placebo, p<0.0001, all secondary endpoints met, well-tolerated safety profile), it is not a financial earnings release but rather a clinical/scientific presentation of investigational drug trial outcomes. The document explicitly states "This presentation includes data for an investigational product not yet approved by regulatory authorities" and focuses on efficacy, safety, and quality-of-life endpoints rather than financial results. However, for a clinical-stage biopharmaceutical company, positive Phase 3 data is material to investors' assessment of the company's prospects and regulatory pathway.
View raw filing on EDGAR →Fidelity Core Real Estate Fund disclosed Q2 2026 quarterly financial results, including a net total return of 1.66%, annualized since-inception return of 9.02%, gross portfolio value of $671.4M, investor equity of $404.3M, and a quarterly dividend of $0.1361/share.
View raw filing on EDGAR →This is an announcement of an upcoming earnings call and financial results disclosure for Q1 fiscal year 2027. While the actual financial results are not yet disclosed in this exhibit (they will be issued "prior to the call" on September 14, 2026), the exhibit is a formal announcement of the earnings event itself, which is a material disclosure that would affect investor assessment of the company's periodic financial performance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 "Results of Operations and Financial Condition." The press release announces quarterly financial results including revenue, operating expenses, net income, and cash position, with the full text furnished as Exhibit 99.1. The disclosure is material as it reports significant financial performance including a $125.9 million net income swing and $172.8 million in cash, alongside material corporate developments (FDA NDA acceptance, IPO completion for $220.8 million gross proceeds).
View raw filing on EDGAR →This is a press release dated September 8, 2026, announcing Can-Fite's Q2 2026 (H1 2026) financial results and clinical progress. The exhibit discloses six-month revenues ($0.20M), R&D expenses ($3.45M), G&A expenses ($1.42M), net loss ($4.60M), and cash position ($7.03M), along with condensed consolidated balance sheets and statements of operations. While the release emphasizes clinical milestones (longer-than-anticipated overall survival in the Phase III HCC study, pancreatic cancer Phase 2a results, and psoriasis Phase 3 interim analysis stage), the core disclosure is the periodic financial results for the first half of 2026, making this an earnings release. The clinical updates are material context for investors assessing the company's pipeline value and cash burn trajectory.
View raw filing on EDGAR →GameStop issued a press release on September 8, 2026 announcing financial results for its second quarter ended August 1, 2026, with net sales of $790.2 million, record operating income of $160.2 million, and net income of $298.7 million, along with an upward revision of fiscal year 2026 Adjusted EBITDA guidance to in excess of $650 million.
View raw filing on EDGAR →EVI Industries issued a press release on September 8, 2026 announcing financial results for the three and twelve months ended June 30, 2026, disclosing record revenue of $446.6 million (up 15%), record gross profit of $140.7 million (up 19%), and record operating income of $15.7 million (up 14%). This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, reporting quarterly and annual financial results.
View raw filing on EDGAR →MIND Technology issued a press release on September 8, 2026 announcing financial results for the fiscal 2027 second quarter ended July 31, 2026, disclosing revenues of $5.6 million, an operating loss of $1.8 million, and a net loss of $1.7 million ($0.19 per share).
View raw filing on EDGAR →This exhibit is a press release announcing unaudited financial results for the fourth quarter and full fiscal year ended June 30, 2026. The document discloses total revenue of US$104.7 million (down 11.4% YoY), net income of US$3.9 million (up 0.8% YoY), and detailed operating metrics. The company also provides forward guidance for Q1 FY2027 revenue of US$20–23 million. This is a discrete earnings announcement, not a periodic financial report filing itself, and is material to investors assessing the registrant's financial performance and strategic transition toward AI-generated content.
View raw filing on EDGAR →PMI furnished a press release (Exhibit 99.1) disclosing updated 2026 full-year and Q3 diluted EPS forecasts, raising the full-year adjusted diluted EPS guidance range to $8.35–$8.50 (representing 10.7%–12.7% growth versus 2025). Although this is a guidance update rather than final results, it constitutes a material earnings disclosure furnished in connection with a conference presentation, consistent with Item 7.01 Regulation FD Disclosure practice for earnings-related announcements.
View raw filing on EDGAR →Braveheart Bio disclosed its unaudited financial results for the second quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes condensed statements of operations and comprehensive loss, balance sheets, and detailed financial metrics (R&D expenses of $11.1M, G&A expenses of $4.8M, net loss of $15.0M, and net loss per share of $2.51). This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial condition and cash runway (estimated to support operations into 2029).
View raw filing on EDGAR →Barnes & Noble Education issued a press release on September 8, 2026 announcing financial results for the fiscal quarter ended August 1, 2026, with detailed consolidated statements of operations showing revenue of $290.6 million, net loss of $12.9 million (improved 29% YoY), and Adjusted EBITDA of $(9.3) million (improved 19% YoY). The filing explicitly states the press release is furnished as Exhibit 99.1 and financial statements as Exhibit 99.2, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →ServiceTitan issued a press release on September 8, 2026 announcing financial results for the fiscal second quarter ended July 31, 2026, including revenue of $292.8 million (21% YoY growth), GAAP operating loss of ($27.6) million, and non-GAAP free cash flow of $50.5 million. The filing includes condensed consolidated financial statements, forward guidance for Q3 and full-year FY2027, and management commentary from the Co-Founders and CEO. This is a standard quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →This 6-K furnishes a press release announcing positive Phase III trial results for Imfinzi plus Imdelltra in small cell lung cancer, demonstrating "statistically significant and highly clinically meaningful improvement in overall survival" versus Imfinzi alone. While technically a clinical trial result rather than financial earnings, this disclosure functions as a material product/pipeline announcement that would affect investor assessment of AstraZeneca's oncology portfolio and commercial prospects. The language emphasizing "unprecedented improvement" and "new standards of care" signals material clinical and commercial significance.
View raw filing on EDGAR →Braze issued a press release on September 8, 2026 announcing financial results for the fiscal quarter ended July 31, 2026, disclosing 26% year-over-year revenue growth to $227.2 million, record second quarter free cash flow of $22 million, and updated full-year guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →Mission Produce announced its fiscal Q3 2026 financial results on September 8, 2026, disclosing total revenue of $450 million (26% increase YoY), net loss of $6.5 million per diluted share, and adjusted net income of $0.18 per diluted share. The press release attached as Exhibit 99.1 contains comprehensive quarterly financial results, segment performance, and forward guidance, which is the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →InnovAge issued a press release on September 8, 2026 announcing financial results for the fiscal fourth quarter and full year ended June 30, 2026. The disclosure includes detailed financial metrics (total revenues of $989.7 million, net loss of $0.7 million, Adjusted EBITDA of $94.6 million), year-over-year comparisons, and forward-looking guidance for fiscal 2027. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →Campbell's issued a press release on September 3, 2026, announcing financial results for the quarter and full year ended August 2, 2026. The disclosure includes detailed quarterly and annual net sales, EBIT, and EPS figures, along with segment operating results and forward guidance for fiscal 2027. This is a standard earnings release attached as Exhibit 99.1 to Item 2.02, disclosing material financial results that would affect a reasonable investor's assessment of the company's performance.
View raw filing on EDGAR →Oxford Industries issued a press release on September 3, 2026, announcing financial results for the fiscal 2026 second quarter ended August 1, 2026. The disclosure includes consolidated net sales of $394 million, GAAP EPS of $3.25, adjusted EPS of $1.34, and revised full-year guidance lowering sales and EPS expectations due to softness in Lilly Pulitzer and macro-economic pressures. This is a standard quarterly earnings release with material financial results and forward guidance.
View raw filing on EDGAR →The Toro Company announced its financial results for the three and nine month periods ended July 31, 2026, with a press release attached as Exhibit 99.1. The disclosure includes key metrics (net sales up 8.4% YoY to $1.23B, reported EPS up 50% YoY to $0.81, adjusted EPS up 7.3% YoY to $1.33), segment performance, and raised full-year guidance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →Brady Corporation issued a press release on September 3, 2026 announcing its fiscal 2026 fourth quarter and full-year financial results, including record annual revenue and adjusted diluted EPS of $5.29 (15% increase), along with fiscal 2027 guidance projecting 23% adjusted diluted EPS growth.
View raw filing on EDGAR →eGain issued a press release on September 3, 2026 announcing financial results for its fiscal 2026 fourth quarter and full year ended June 30, 2026. The disclosure includes comprehensive financial highlights (revenue, gross margin, net income, EBITDA, cash position), forward guidance for Q1 and FY2027, and key business metrics. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →Pro-Dex issued a press release on September 3, 2026, announcing financial results for its fourth fiscal quarter and full fiscal year ended June 30, 2026. The disclosure includes detailed quarterly and annual net sales ($20.4M and $77.5M respectively), gross profit, operating income, and net income ($2.9M and $13.7M respectively) with per-share metrics. This is a standard earnings release attached as Exhibit 99.1 and disclosed under Item 2.02, which is the designated Item for earnings announcements.
View raw filing on EDGAR →This is a press release announcing Amber International's Q2 2026 unaudited financial results, with total revenue of US$13.9 million (up 38.8% QoQ), gross margin expansion to 79.5%, and a return to positive operating income and Adjusted EBITDA. The disclosure includes detailed financial metrics, business highlights, and management commentary on the company's strategic pivot to specialized AI agents. This is a material earnings announcement that would affect a reasonable investor's assessment of the registrant's financial performance and strategic direction.
View raw filing on EDGAR →This is a press release announcing preliminary unaudited financial results for the six months ended June 30, 2026. The exhibit discloses revenue of $9.9 million (24.6% growth), gross profit of $8.6 million (32.0% increase), and a turnaround to net income of $13,499 from a net loss of $(11.4) million in the prior-year period. The release includes consolidated balance sheets and statements of operations, making it a discrete earnings announcement rather than a periodic financial report filing.
View raw filing on EDGAR →This is an earnings release disclosing interim financial results for Q2 2026 (three months ended June 30, 2026). The exhibit presents total revenues of $96.8 million, operating income of $15.6 million, net income of $3.4 million, and Adjusted EBITDA of $57.6 million, along with detailed financial analysis and operational highlights. The document is explicitly titled "EARNINGS RELEASE—INTERIM RESULTS FOR THE PERIOD ENDED JUNE 30, 2026" and includes comparative analysis to prior quarters and year-over-year results, which is characteristic of a quarterly earnings disclosure.
View raw filing on EDGAR →This is a clear earnings release for Q3 2026 (three months ended July 31, 2026) filed under Item 2.02. The press release discloses comprehensive financial results including net sales of $501.8 million, net income of $26.5 million, diluted EPS of $0.58, and adjusted EBITDA of $72.7 million, along with segment performance, balance sheet metrics, and cash flow data. The filing explicitly states "On September 3, 2026, the Registrant issued a press release" and the exhibit contains the full quarterly earnings announcement with detailed financial tables and management commentary.
View raw filing on EDGAR →This is a press release disclosing BRP's second quarter fiscal 2027 financial results, including revenues of $2,236.8 million (up 18.5%), net loss of $136.8 million, and normalized EBITDA of $138.8 million. The release also includes revised full-year FY27 guidance and highlights material operational developments (product launches, market share gains, financial leadership transition). This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →This is a press release announcing Hello Group Inc.'s unaudited financial results for the second quarter of 2026, including net revenues (RMB2,486.0 million), net income attributable to shareholders (RMB237.4 million), and diluted EPS (RMB1.52 per ADS). The document explicitly states "Hello Group Inc. Announces Unaudited Financial Results for the Second Quarter of 2026" and provides detailed quarterly and first-half financial performance metrics, making it a classic earnings release disclosure material to investors.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 fiscal 2026 ended July 31, 2026. The Item 2.02 disclosure announces financial results including net revenue of $302.0 million (up 2.7% YoY), net income of $3.5 million ($0.11 EPS), and provides forward guidance for Q3 and full fiscal 2026. The press release is furnished as Exhibit 99.1 and includes detailed financial highlights, balance sheet data, and management commentary—all hallmarks of an earnings_release classification.
View raw filing on EDGAR →Genesco Inc. issued a press release on September 3, 2026, announcing second quarter fiscal 2027 results for the period ended August 1, 2026. The disclosure includes net sales of $530 million, comparable sales metrics by segment, gross margin and operating income analysis, GAAP and adjusted EPS figures, and updated full-year guidance raising adjusted EPS to the high end of the $2.00 to $2.40 range. This is a standard quarterly earnings release with financial results and forward guidance, clearly falling under Item 2.02 and the earnings_release event type.
View raw filing on EDGAR →Duluth Holdings disclosed financial results for fiscal Q2 2026 ended August 2, 2026, reporting net income of $18.4 million (vs. $1.3 million prior year) and adjusted EBITDA of $27.0 million (vs. $12.0 million prior year), while raising full-year adjusted EBITDA guidance to $38–$42 million.
View raw filing on EDGAR →This exhibit is a press release announcing StealthGas Inc.'s unaudited financial and operating results for the second quarter and six months ended June 30, 2026. The document discloses net income of $17.3 million (Q2) and $33.2 million (6M), earnings per share of $0.46 (Q2) and $0.89 (6M), revenues of $42.9 million (Q2) and $85.8 million (6M), along with detailed operational metrics and fleet updates. This is a classic earnings release announcing periodic financial results to the market.
View raw filing on EDGAR →Planet Labs issued a press release on September 3, 2026 announcing financial results for its second fiscal quarter ended July 31, 2026, disclosing record quarterly revenue of $116.1 million (58% YoY growth), adjusted EBITDA profit of $13.9 million, and cash position of $865.4 million. The filing explicitly states the press release is attached as Exhibit 99.1 and is incorporated by reference, which is the standard disclosure mechanism for earnings releases under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release disclosing Smith & Wesson's first quarter fiscal 2027 financial results. The press release (Exhibit 99.1) reports Q1 net sales of $112.6 million (up 32.3% YoY), gross margin of 28.7%, and EPS of $0.06/share (versus a loss of $0.08 in the prior year). The filing explicitly states it is "furnishing the disclosure in this Item 2.02 in connection with the disclosure of information in the form of the textual information from a press release issued on September 3, 2026," which is the standard Item 2.02 treatment for quarterly earnings announcements.
View raw filing on EDGAR →This is a classic earnings release disclosure under Item 2.02. The company issued a press release on September 3, 2026 announcing financial results for Q2 2026 (quarter ended June 30, 2026), including condensed balance sheets and statements of operations showing R&D expenses of $21.2M, G&A expenses of $4.6M, and a net loss of $25.8M. The press release is attached as Exhibit 99.1 and incorporates financial results alongside recent business highlights including the completed IPO and clinical trial progress.
View raw filing on EDGAR →Ambarella issued a press release on September 3, 2026 announcing its financial results for the second quarter of fiscal year 2027 ended July 31, 2026. The disclosure includes detailed GAAP and non-GAAP financial metrics (revenue of $108.1 million, gross margin, net loss per share), six-month comparisons, and forward guidance for Q3 FY2027. This is a standard quarterly earnings release attached as Exhibit 99.1, clearly falling under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →This is a press release disclosing financial results for a three-month period (June–August 2026), reporting over US$180 million in revenue. Although the revenue is preliminary and unaudited, the disclosure of periodic financial performance in press-release form is characteristic of an earnings_release. The material acquisition of QC Capital on June 15, 2026, and its contribution to the reported revenue make this disclosure material to investors assessing the company's financial trajectory and integration success.
View raw filing on EDGAR →Docusign disclosed financial results for the second fiscal quarter ended July 31, 2026, including revenue of $875.7 million (9% YoY growth), GAAP net income per diluted share of $0.40, and non-GAAP net income per diluted share of $1.16. The company also raised full-year fiscal 2027 guidance for revenue, ARR, and IAM's percentage of total ARR. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →This is a news release dated September 3, 2026, disclosing New Pacific's financial results for the three months and year ended June 30, 2026. The document reports net loss of $0.99 million and $4.19 million for the respective periods, working capital of $37.76 million, and operating expenses. Although the company is in exploration/development stage (not yet producing), the disclosure of periodic financial results in press-release format is the hallmark of an earnings_release. The material highlights—including the Updated Carangas PEA Technical Report with $2.65 billion NPV and 35.9% IRR, signing of Administrative Mining Contracts, and executive appointments—are disclosed alongside the financial results, making this a material event affecting investor assessment of the registrant's financial position and project progress.
View raw filing on EDGAR →This is a clear earnings release for Q2 fiscal 2026 (ended August 2, 2026) disclosing quarterly financial results including revenue ($2.4 billion, down 4%), comparable sales (down 9%), diluted EPS ($2.92), and revised full-year 2026 guidance (revenue expected to decline 5-7%). The press release is attached as Exhibit 99.1 and Item 2.02 explicitly states the Company "issued a press release announcing its financial results for the second quarter ended August 2, 2026."
View raw filing on EDGAR →VersaBank announced third quarter fiscal 2026 financial results for the period ended July 31, 2026, reporting net income of $10.1 million (53% YoY growth), adjusted core net income of $12.3 million (27% YoY growth), revenue of $38.8 million (23% YoY growth), and total assets of $6.9 billion (26% YoY growth), with segmented results by business line and management commentary.
View raw filing on EDGAR →